Literature DB >> 17451082

Insulin resistance and metabolic syndrome in children of parents with diabetes mellitus.

Sebnem Altinli1, Murat Elevli, Ayse Ayaz Ozkul, Pinar Gizem Kara, Kubilay Karsidag, Macit Dogru.   

Abstract

The aim of this prospective study was to research features of insulin resistance and metabolic syndrome in offspring of diabetic parents and to find out whether there is a risk of developing type 2 diabetes mellitus (DM) in these children. Study participants were 30 children of parents with type 1 DM (DM1) (Group I) and 11 children of parents with type 2 DM (DM2) (Group II) who were being followed up in the Diabetes Department of Haseki Research and Training Hospital. The results were compared with a control group of 17 children in the same age group (Group III). There were no statistically significant differences between the Group I and the control group in fasting blood glucose, oral glucose tolerance test values, 1st 2nd and hour insulin, homeostasis model assessment (HOMA) values, body mass index (BMI), systolic and diastolic blood pressure, and lipid parameters, i.e. HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, total cholesterol, and triglycerides. Fasting, 1st and 2nd hour blood insulin levels, HOMA values, BMI, and systolic blood pressure values were significantly higher in Group II compared to the control group (p < 0.05). There were no statistically significant differences between Group II and the control group in lipid parameters, fasting blood glucose, OGTT values, or diastolic blood pressure. We conclude that in our population there is a tendency of insulin resistance and metabolic syndrome in the offspring of parents with DM2, and a risk for developing DM2. Thus, children of patients with DM2 should be followed up so as to recognize early metabolic defects of glucose metabolism and to plan effective preventive efforts to reduce cardiovascular and atherosclerotic risk factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451082     DOI: 10.1515/jpem.2007.20.3.431

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

1.  Insulin resistance, secretion and breakdown are increased 9 months following severe burn injury.

Authors:  Melanie G Cree; Ricki Y Fram; David Barr; David Chinkes; Robert R Wolfe; David N Herndon
Journal:  Burns       Date:  2008-07-30       Impact factor: 2.744

2.  Association of parental history of diabetes with cardiovascular disease risk factors in children with type 2 diabetes.

Authors:  Jennifer R Law; Jeanette M Stafford; Ralph B D'Agostino; Angela Badaru; Tessa L Crume; Dana Dabelea; Lawrence M Dolan; Jean M Lawrence; David J Pettitt; Elizabeth J Mayer-Davis
Journal:  J Diabetes Complications       Date:  2015-02-10       Impact factor: 2.852

Review 3.  Adipose tissue and metabolic syndrome: too much, too little or neither.

Authors:  Scott M Grundy
Journal:  Eur J Clin Invest       Date:  2015-09-13       Impact factor: 4.686

4.  Comparison of the effects of sibling and parental history of type 2 diabetes on metabolic syndrome.

Authors:  Hsuan Chiu; Mei-Yueh Lee; Pei-Yu Wu; Jiun-Chi Huang; Szu-Chia Chen; Jer-Ming Chang
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

5.  Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics.

Authors:  Gopal Krushna Pal; Chandrasekaran Adithan; Palghat Hariharan Ananthanarayanan; Pravati Pal; Nivedita Nanda; Thiyagarajan Durgadevi; Venugopal Lalitha; Avupati Naga Syamsunder; Tarun Kumar Dutta
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

6.  The influence of familial predisposition to cardiovascular complications upon childhood obesity treatment.

Authors:  Louise A Nielsen; Christine Bøjsøe; Julie T Kloppenborg; Cæcilie Trier; Michael Gamborg; Jens-Christian Holm
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.